Compare BGC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | SRRK |
|---|---|---|
| Founded | 1945 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.6B |
| IPO Year | 1999 | 2018 |
| Metric | BGC | SRRK |
|---|---|---|
| Price | $9.46 | $47.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $14.50 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $2,640,884,000.00 | N/A |
| Revenue This Year | $36.53 | N/A |
| Revenue Next Year | $11.33 | $20,029.43 |
| P/E Ratio | $27.14 | ★ N/A |
| Revenue Growth | ★ 24.59 | N/A |
| 52 Week Low | $7.24 | $22.71 |
| 52 Week High | $10.96 | $49.82 |
| Indicator | BGC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 57.31 |
| Support Level | $8.81 | $44.10 |
| Resistance Level | $9.18 | $48.00 |
| Average True Range (ATR) | 0.29 | 2.39 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 88.89 | 69.64 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.